Why Use DEFINITY®?
DEFINITY® makes a clear difference in the clinical setting*
|
Clinical Value of Contrast Echocardiography Presented by: Miguel A. Quiñones, MD, FACC Professor of Medicine Weill Cornell Medical College New York, New York Methodist DeBakey Cardiology Associates Houston, Texas View Archived Webcast Presentation |
![]() |
------------------------------------------------ Contrast Echocardiography: My Clinical Experience Presented by: Howard Leong-Poi, MD, FRCPC St. Michael's Hospital University of Toronto Audio Presentation |
It should be noted that Lantheus Medical Imaging has not done specific clinical trials on these patient types.
- The use of contrast may reduce the need for subsequent testing 3,5
- The American Society of Echocardiography endorses the use of imaging agents to improve endocardial border delineation in patients with suboptimal echocardiograms 1,4
- Since its launch in 2001, DEFINITY® has been administered to over 2,000,000 patients6
*Many patients benefit from DEFINITY®'s enhancement1,2,3,5,7
1. Mulvagh SL et al. Contrast Echocardiography: Current and future applications. J Am Soc Echocardiogr 2000; 13: 331-42.
2. Burgess P et al. Performing an Echocardiographic Examination with a Contrast Agent: A Series on Contrast Echocardiography, Article 2. JASE 2000; 13: 629-636.
3. Shaw LJ et al. Clinical and economic outcomes assessment with myocardial contrast echocardiography Heart 1999; 82: 16-21.
4. Waggoner AD et al. Guidelines for the cardiac sonographer in the performance of contrast echocardiography:
recommendations of the American Society of Echocardiography Council on Cardiac Sonography. J Am Soc Echocardiogr 2001;14: 417-420.
5. Kitzman DW et al. Efficacy and Safety of the Novel Ultrasound Contrast Agent Perflutren (Definity) in Patients With Suboptimal Baseline Left Ventricular Echocardiographic Images. Am J Cardiol 2000; 86: 669-674.
6. Source: The Echocardiography Monthly Monitor: United States, October 2001-September 2008, Arlington Medical Resources, Inc., Malvern, PA ©2008 Arlington Medical Resources, Inc. All rights reserved. Reproduction, distribution, transmission or publication is prohibited.
7. Data on file, Lantheus Medical Imaging, Inc.
INDICATIONS
Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.
CONTRAINDICATIONS
Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.
IMPORTANT SAFETY INFORMATION
WARNING: Serious Cardiopulmonary Reactions Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration.
|
In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration (see ADVERSE REACTIONS). The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.
Please See Full Prescribing Information and Letter to Healthcare Providers.
